Costs of treating dystonias and hemifacial spasm with botulinum toxin A

Richard C. Dodel, Annette Kirchner, Rudolf Koehne-Volland, Gabriella Künig, Andres Ceballos-Baumann, Markus Naumann, Allison Brashear, Hans P. Richter, Thomas D. Szucs, Wolfgang H. Oertel

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Botulinum toxin (BTX) has become a safe and effective therapeutic tool in the treatment of a variety of neurological disorders, especially dystonias. One major disadvantage, however, is the high cost of a single injection of BTX. In this study of 835 patients, we calculated the cost of treatment with BTX serotype A (BTX-A) for different dystonias and hemifacial spasm. The annual expenditure per patient for BTX-A injections in this cohort totalled (mean ± standard deviation) 1030 Deutschmarks (DM) [1996 values] ± DM610 [$US570 ± $US340; 230 ± 130 pounds sterling (and)I for blepharospasm (n = 158), DM1450 ± DM1520 ($US800 ± $US830; £310 ± £280) for craniocervical dystonia (n = 148), and DM1480 ± DM780 ($US810 ± $US430; £330 ± £180) for oromandibular dystonia (n = 16), while the treatment of cervical dystonia consumed DM4590 ± DM2060 ($US2520 ± $US1130; £960 ± £420) [n = 362] per patient. In order to alleviate symptoms in patients with hemifacial spasm (n = 151), DM510 ± DM270 ($US280 ± $US150; £110 ± £60) had to be spent annually. The expenses for surgical therapy for cervical dystonia were DM 10 120 ± DM1900 (n = 54). No major differences concerning expenditure could be found in this study between the 2 available preparations of BTX. However, there appeared to be a lower rate of adverse effects with the Botox® formulation, compared with the Dysport® formulation, of BTX-A (this difference was statistically significant, i.e. p < 0.001). Although the cost of an individual injection is high, other cost factors also substantially contribute to the societal costs of adult-onset dystonias. Some of these costs may be attenuated with the use of BTX. The subjective and objective relief of these socially devastating and sometimes painful conditions rewards the expenditure associated with the use of BTX-A.

Original languageEnglish (US)
Pages (from-to)695-706
Number of pages12
JournalPharmacoEconomics
Volume12
Issue number6
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

Hemifacial Spasm
Type A Botulinum Toxins
Dystonia
Botulinum Toxins
Costs and Cost Analysis
Health Expenditures
Torticollis
Injections
Blepharospasm
Dystonic Disorders
Therapeutics
Nervous System Diseases
Reward
Health Care Costs

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Dodel, R. C., Kirchner, A., Koehne-Volland, R., Künig, G., Ceballos-Baumann, A., Naumann, M., ... Oertel, W. H. (1997). Costs of treating dystonias and hemifacial spasm with botulinum toxin A. PharmacoEconomics, 12(6), 695-706. https://doi.org/10.2165/00019053-199712060-00009

Costs of treating dystonias and hemifacial spasm with botulinum toxin A. / Dodel, Richard C.; Kirchner, Annette; Koehne-Volland, Rudolf; Künig, Gabriella; Ceballos-Baumann, Andres; Naumann, Markus; Brashear, Allison; Richter, Hans P.; Szucs, Thomas D.; Oertel, Wolfgang H.

In: PharmacoEconomics, Vol. 12, No. 6, 01.01.1997, p. 695-706.

Research output: Contribution to journalArticle

Dodel, RC, Kirchner, A, Koehne-Volland, R, Künig, G, Ceballos-Baumann, A, Naumann, M, Brashear, A, Richter, HP, Szucs, TD & Oertel, WH 1997, 'Costs of treating dystonias and hemifacial spasm with botulinum toxin A', PharmacoEconomics, vol. 12, no. 6, pp. 695-706. https://doi.org/10.2165/00019053-199712060-00009
Dodel RC, Kirchner A, Koehne-Volland R, Künig G, Ceballos-Baumann A, Naumann M et al. Costs of treating dystonias and hemifacial spasm with botulinum toxin A. PharmacoEconomics. 1997 Jan 1;12(6):695-706. https://doi.org/10.2165/00019053-199712060-00009
Dodel, Richard C. ; Kirchner, Annette ; Koehne-Volland, Rudolf ; Künig, Gabriella ; Ceballos-Baumann, Andres ; Naumann, Markus ; Brashear, Allison ; Richter, Hans P. ; Szucs, Thomas D. ; Oertel, Wolfgang H. / Costs of treating dystonias and hemifacial spasm with botulinum toxin A. In: PharmacoEconomics. 1997 ; Vol. 12, No. 6. pp. 695-706.
@article{8bdf6c34bbf44d6ebee4440219c49141,
title = "Costs of treating dystonias and hemifacial spasm with botulinum toxin A",
abstract = "Botulinum toxin (BTX) has become a safe and effective therapeutic tool in the treatment of a variety of neurological disorders, especially dystonias. One major disadvantage, however, is the high cost of a single injection of BTX. In this study of 835 patients, we calculated the cost of treatment with BTX serotype A (BTX-A) for different dystonias and hemifacial spasm. The annual expenditure per patient for BTX-A injections in this cohort totalled (mean ± standard deviation) 1030 Deutschmarks (DM) [1996 values] ± DM610 [$US570 ± $US340; 230 ± 130 pounds sterling (and)I for blepharospasm (n = 158), DM1450 ± DM1520 ($US800 ± $US830; £310 ± £280) for craniocervical dystonia (n = 148), and DM1480 ± DM780 ($US810 ± $US430; £330 ± £180) for oromandibular dystonia (n = 16), while the treatment of cervical dystonia consumed DM4590 ± DM2060 ($US2520 ± $US1130; £960 ± £420) [n = 362] per patient. In order to alleviate symptoms in patients with hemifacial spasm (n = 151), DM510 ± DM270 ($US280 ± $US150; £110 ± £60) had to be spent annually. The expenses for surgical therapy for cervical dystonia were DM 10 120 ± DM1900 (n = 54). No major differences concerning expenditure could be found in this study between the 2 available preparations of BTX. However, there appeared to be a lower rate of adverse effects with the Botox{\circledR} formulation, compared with the Dysport{\circledR} formulation, of BTX-A (this difference was statistically significant, i.e. p < 0.001). Although the cost of an individual injection is high, other cost factors also substantially contribute to the societal costs of adult-onset dystonias. Some of these costs may be attenuated with the use of BTX. The subjective and objective relief of these socially devastating and sometimes painful conditions rewards the expenditure associated with the use of BTX-A.",
author = "Dodel, {Richard C.} and Annette Kirchner and Rudolf Koehne-Volland and Gabriella K{\"u}nig and Andres Ceballos-Baumann and Markus Naumann and Allison Brashear and Richter, {Hans P.} and Szucs, {Thomas D.} and Oertel, {Wolfgang H.}",
year = "1997",
month = "1",
day = "1",
doi = "10.2165/00019053-199712060-00009",
language = "English (US)",
volume = "12",
pages = "695--706",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Costs of treating dystonias and hemifacial spasm with botulinum toxin A

AU - Dodel, Richard C.

AU - Kirchner, Annette

AU - Koehne-Volland, Rudolf

AU - Künig, Gabriella

AU - Ceballos-Baumann, Andres

AU - Naumann, Markus

AU - Brashear, Allison

AU - Richter, Hans P.

AU - Szucs, Thomas D.

AU - Oertel, Wolfgang H.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Botulinum toxin (BTX) has become a safe and effective therapeutic tool in the treatment of a variety of neurological disorders, especially dystonias. One major disadvantage, however, is the high cost of a single injection of BTX. In this study of 835 patients, we calculated the cost of treatment with BTX serotype A (BTX-A) for different dystonias and hemifacial spasm. The annual expenditure per patient for BTX-A injections in this cohort totalled (mean ± standard deviation) 1030 Deutschmarks (DM) [1996 values] ± DM610 [$US570 ± $US340; 230 ± 130 pounds sterling (and)I for blepharospasm (n = 158), DM1450 ± DM1520 ($US800 ± $US830; £310 ± £280) for craniocervical dystonia (n = 148), and DM1480 ± DM780 ($US810 ± $US430; £330 ± £180) for oromandibular dystonia (n = 16), while the treatment of cervical dystonia consumed DM4590 ± DM2060 ($US2520 ± $US1130; £960 ± £420) [n = 362] per patient. In order to alleviate symptoms in patients with hemifacial spasm (n = 151), DM510 ± DM270 ($US280 ± $US150; £110 ± £60) had to be spent annually. The expenses for surgical therapy for cervical dystonia were DM 10 120 ± DM1900 (n = 54). No major differences concerning expenditure could be found in this study between the 2 available preparations of BTX. However, there appeared to be a lower rate of adverse effects with the Botox® formulation, compared with the Dysport® formulation, of BTX-A (this difference was statistically significant, i.e. p < 0.001). Although the cost of an individual injection is high, other cost factors also substantially contribute to the societal costs of adult-onset dystonias. Some of these costs may be attenuated with the use of BTX. The subjective and objective relief of these socially devastating and sometimes painful conditions rewards the expenditure associated with the use of BTX-A.

AB - Botulinum toxin (BTX) has become a safe and effective therapeutic tool in the treatment of a variety of neurological disorders, especially dystonias. One major disadvantage, however, is the high cost of a single injection of BTX. In this study of 835 patients, we calculated the cost of treatment with BTX serotype A (BTX-A) for different dystonias and hemifacial spasm. The annual expenditure per patient for BTX-A injections in this cohort totalled (mean ± standard deviation) 1030 Deutschmarks (DM) [1996 values] ± DM610 [$US570 ± $US340; 230 ± 130 pounds sterling (and)I for blepharospasm (n = 158), DM1450 ± DM1520 ($US800 ± $US830; £310 ± £280) for craniocervical dystonia (n = 148), and DM1480 ± DM780 ($US810 ± $US430; £330 ± £180) for oromandibular dystonia (n = 16), while the treatment of cervical dystonia consumed DM4590 ± DM2060 ($US2520 ± $US1130; £960 ± £420) [n = 362] per patient. In order to alleviate symptoms in patients with hemifacial spasm (n = 151), DM510 ± DM270 ($US280 ± $US150; £110 ± £60) had to be spent annually. The expenses for surgical therapy for cervical dystonia were DM 10 120 ± DM1900 (n = 54). No major differences concerning expenditure could be found in this study between the 2 available preparations of BTX. However, there appeared to be a lower rate of adverse effects with the Botox® formulation, compared with the Dysport® formulation, of BTX-A (this difference was statistically significant, i.e. p < 0.001). Although the cost of an individual injection is high, other cost factors also substantially contribute to the societal costs of adult-onset dystonias. Some of these costs may be attenuated with the use of BTX. The subjective and objective relief of these socially devastating and sometimes painful conditions rewards the expenditure associated with the use of BTX-A.

UR - http://www.scopus.com/inward/record.url?scp=9844264279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9844264279&partnerID=8YFLogxK

U2 - 10.2165/00019053-199712060-00009

DO - 10.2165/00019053-199712060-00009

M3 - Article

C2 - 10175981

AN - SCOPUS:9844264279

VL - 12

SP - 695

EP - 706

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 6

ER -